Key result
GO SOAR calculator predicts 30-day postoperative mortality with ~0.75 AUROC in gynaecological oncology surgery.
Why the study?
Universal surgical risk calculators are not validated for and poorly predict postoperative morbidity and mortality in women undergoing gynaecological oncology surgery, impairing risk communication and preoperative optimization.
Does the GO SOAR surgical risk calculator improve prediction of 30-day postoperative mortality and morbidity compared to established all-purpose calculators in women undergoing gynaecological oncology surgery?
Cohort (n=2,227)
Yes
Does the GO SOAR surgical risk calculator improve prediction of 30-day postoperative mortality and morbidity compared to established all-purpose calculators in women undergoing gynaecological oncology surgery?
Effect estimate: AUROC 0.752 (95% CI 0.570-0.935)
The GO SOAR surgical risk calculator provides accurate, data-driven predictions of 30-day postoperative morbidity and mortality for gynaecological oncology surgery, outperforming universal calculators at a clinically significant 90% specificity threshold.
GO SOAR full model shows moderate discrimination for 30-day mortality; hypothesis-generating and should not yet change preoperative risk assessment in gynaecological oncology.
Background/Objectives: Universal surgical risk calculators are not validated for use and poorly predict postoperative morbidity and mortality for women undergoing gynaecological oncology surgery. This adversely affects communication of risk resulting in poorly informed decisions and missed opportunities for medical optimization to mitigate risk preoperatively. We present the development and external validation of our novel GO SOAR surgical risk calculator for use to preoperatively predict postoperative thirty-day surgical morbidity and mortality in relation to gynaecological oncology surgeries. Methods: New logistic regression models were developed using the GO SOAR1 training cohort (n = 1811) and externally validated in an independent prospective cohort (n = 416) for two outcomes: thirty-day postoperative mortality (alive versus dead) and thirty-day postoperative morbidity (any complication (Clavien–Dindo I–V) versus none). Performance of the GO SOAR models was compared against established all-purpose surgical risk calculators (SORT/POSSUM/P-POSSUM/NSQIP). Model discrimination was assessed with sensitivity calculated at a clinically significant prespecified specificity threshold of 90%. Results: For mortality, AUROC was 0.752 (95% CI 0.570–0.935) for GO SOAR full and 0.795 (95% CI 0.660–0.930) for GO SOAR condensed; corresponding sensitivities at 90% specificity were 57.1% and 42.9%. For morbidity, AUROC was 0.698 (95% CI 0.641–0.755) and 0.703 (95% CI 0.646–0.760) for the full and condensed models, respectively, with sensitivities of 30.4% and 32.1% at 90% specificity. Conclusions: The GO SOAR model using a data-driven, gynaecological-oncology-specific approach at 90% specificity, achieved the highest observed sensitivity among the evaluated calculators. Accurate surgical risk predictions are crucial for major oncological surgery, where complications can diminish quality of life and affect long-term cancer survival. A model such as the GO SOAR surgical risk calculator that uses readily available preoperative data, regardless of income setting, is essential in reducing global disparities in surgical outcomes.
No takes yet. Share an insight, caveat, or question.
Gaba et al. (2026) conducted a cohort in Gynaecological malignancies (n=2,227). GO SOAR surgical risk calculator vs. Established all-purpose surgical risk calculators (SORT, POSSUM, P-POSSUM, NSQIP) was evaluated on 30-day postoperative mortality (AUROC) (AUROC 0.752, 95% CI 0.570-0.935). The GO SOAR full surgical risk calculator achieved an AUROC of 0.752 for predicting 30-day postoperative mortality in women undergoing gynaecological oncology surgery.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: